CN1096673A - 注射用药物组合物 - Google Patents

注射用药物组合物 Download PDF

Info

Publication number: CN1096673A
Authority: CN; China
Prior art keywords: acid; solution; value; injectable; compositions according
Prior art date: 1992-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN93115293A

Other languages

English (en)

Chinese (zh)

Inventor

罗宾·露易斯·艾略特

各里格里·保罗·汉戴克

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mayne Pharma International Pty Ltd

Fording Inc

Original Assignee

Fording Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-27

Filing date

1993-11-26

Publication date

1994-12-28

1993-11-26 Application filed by Fording Inc filed Critical Fording Inc

1994-12-28 Publication of CN1096673A publication Critical patent/CN1096673A/zh

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 17
239000007924 injection Substances 0.000 title description 2
238000002347 injection Methods 0.000 title description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 41
229930012538 Paclitaxel Natural products 0.000 claims abstract description 36
229960001592 paclitaxel Drugs 0.000 claims abstract description 36
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 36
239000002253 acid Substances 0.000 claims abstract description 12
229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims abstract description 11
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims abstract description 11
239000008389 polyethoxylated castor oil Substances 0.000 claims abstract description 11
229960004106 citric acid Drugs 0.000 claims description 9
238000000034 method Methods 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
229960004543 anhydrous citric acid Drugs 0.000 claims description 4
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229960002303 citric acid monohydrate Drugs 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
239000007972 injectable composition Substances 0.000 claims 4
229940102223 injectable solution Drugs 0.000 claims 3
-1 Aspartic acid Benzenesulfonic acid Benzoic acid Hydrochloric acid Sulphuric acid Phosphoric acid Nitric acid Tartaric acid Chemical compound 0.000 claims 1
BKPIHJHQZLUDLA-UHFFFAOYSA-N C(CCC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.C(C(O)C)(=O)O Chemical compound C(CCC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.C(C(O)C)(=O)O BKPIHJHQZLUDLA-UHFFFAOYSA-N 0.000 claims 1
ZMZINYUKVRMNTG-UHFFFAOYSA-N acetic acid;formic acid Chemical compound OC=O.CC(O)=O ZMZINYUKVRMNTG-UHFFFAOYSA-N 0.000 claims 1
239000000243 solution Substances 0.000 description 23
229960000935 dehydrated alcohol Drugs 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000012535 impurity Substances 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
102000029749 Microtubule Human genes 0.000 description 3
108091022875 Microtubule Proteins 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229960004756 ethanol Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000004688 microtubule Anatomy 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000001117 sulphuric acid Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
239000010103 Podophyllin Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
241001116500 Taxus Species 0.000 description 1
241000202349 Taxus brevifolia Species 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940068582 podophyllin Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CN93115293A 1992-11-27 1993-11-26 注射用药物组合物 Pending CN1096673A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPL607492		1992-11-27
AUPL6074		1992-11-27

Publications (1)

Publication Number	Publication Date
CN1096673A true CN1096673A (zh)	1994-12-28

Family

ID=3776561

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN93115293A Pending CN1096673A (zh)	1992-11-27	1993-11-26	注射用药物组合物
CN93120529A Expired - Fee Related CN1047305C (zh)	1992-11-27	1993-11-27	可注射的组合物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN93120529A Expired - Fee Related CN1047305C (zh)	1992-11-27	1993-11-27	可注射的组合物

Country Status (8)

Country	Link
KR (1)	KR100371062B1 (2)
CN (2)	CN1096673A (2)
AU (1)	AU5553894A (2)
IL (2)	IL107776A0 (2)
IN (1)	IN176188B (2)
NZ (1)	NZ258044A (2)
WO (1)	WO1994012198A1 (2)
ZA (1)	ZA938844B (2)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1069693C (zh) *	1995-09-28	2001-08-15	Basf公司	烷氧基化脂肪纯化的方法
CN1101677C (zh) *	1997-05-30	2003-02-19	韩万愚	含有紫杉醇的药用注射溶液
WO2009043226A1 (en) *	2007-09-30	2009-04-09	Jiangsu Hengrui Medicine Co., Ltd.	A stable liquid composition comprising taxan derivatives and its preparation method.
CN101829051A (zh) *	2010-05-31	2010-09-15	南昌弘益科技有限公司	1’-乙酰氧基胡椒酚乙酸酯注射液
CN1899615B (zh) *	2001-03-26	2011-02-02	拜尔舍林药物股份公司	预防再狭窄的制剂
CN108136071A (zh) *	2015-09-15	2018-06-08	W.L.戈尔及同仁股份有限公司	药物组合物和涂料

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2149150C (en) *	1992-11-27	2000-08-01	David R. Carver	Injectable taxol composition with improved stability
TW406020B (en) *	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (fr) *	1994-09-28	1996-07-05	Bristol Myers Squibb Co	Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
NL9500340A (nl) *	1995-02-22	1996-10-01	Yew Tree Pharmaceuticals B V	Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5686488A (en) *	1995-08-25	1997-11-11	Alcon Laboratories, Inc.	Polyethoxylated castor oil products as anti-inflammatory agents
AU724842B2 (en) *	1995-12-21	2000-09-28	Genelabs Technologies, Inc.	Taxane composition and method
KR100191446B1 (ko) *	1996-05-02	1999-06-15	송영욱	파클리탁셀 함유 전신성 홍반성 낭창치료제
KR100330373B1 (ko) *	1996-05-28	2002-11-07	주식회사한국신약	탁솔을 함유한 주사용 약제 조성물
KR100358934B1 (ko) *	1996-09-13	2003-01-29	주식회사한국신약	탁솔을함유한주사용약제조성물
US6045808A (en) *	1997-01-31	2000-04-04	Pharmacia & Upjohn Company	Method for removing high boiling solvents from drug formulations by vacuum drying
ATE226070T1 (de) *	1997-05-30	2002-11-15	Man Woo Han	Taxol enthaltende pharmazeutische injektionslösung
BE1011216A3 (fr) *	1997-06-13	1999-06-01	Thissen En Abrege L T B Lab	Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US6071952A (en) *	1998-12-02	2000-06-06	Mylan Pharmaceuticals, Inc.	Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
JP2004536026A (ja)	2000-11-28	2004-12-02	トランスフォームファーマシューティカルズ，インコーポレーティッド．	パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
KR100774366B1 (ko) *	2001-09-10	2007-11-08	주식회사 중외제약	파클리탁셀 주사제 조성물
CZ294371B6 (cs) *	2002-06-10	2004-12-15	Pliva - Lachema, A. S.	Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
SI2108362T1 (sl) *	2002-06-26	2013-08-30	Medigene Ag	Kationski nosilni sistem, ki vsebuje taksan
EP2308467A3 (en) *	2005-06-17	2011-06-22	Hospira Australia Pty Ltd	Liquid pharmaceutical formulations of docetaxel
US7771751B2 (en)	2005-08-31	2010-08-10	Abraxis Bioscience, Llc	Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CN103432109B (zh) *	2013-09-01	2015-09-23	吴静	紫杉醇的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ224497A (en) *	1987-05-18	1990-04-26	Janssen Pharmaceutica Nv	Pharmaceutical composition comprising flunarizine
US5157049A (en) *	1988-03-07	1992-10-20	The United States Of America As Represented By The Department Of Health & Human Services	Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) *	1989-03-09	1990-10-02	University Of Kansas	Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) *	1989-11-14	1992-08-04	Florida State University	Method for preparation of taxol using an oxazinone
TW223634B (2) *	1991-03-18	1994-05-11	Kingston David G I
EP0580759B1 (en) *	1991-04-19	1999-05-26	The University Of Mississippi	Methods and compositions for isolating taxanes

1993
- 1993-11-25 KR KR1019940702575A patent/KR100371062B1/ko not_active Expired - Fee Related
- 1993-11-25 NZ NZ258044A patent/NZ258044A/en not_active IP Right Cessation
- 1993-11-25 AU AU55538/94A patent/AU5553894A/en not_active Abandoned
- 1993-11-25 WO PCT/AU1993/000599 patent/WO1994012198A1/en not_active Ceased
- 1993-11-26 ZA ZA938844A patent/ZA938844B/xx unknown
- 1993-11-26 CN CN93115293A patent/CN1096673A/zh active Pending
- 1993-11-26 IL IL10777693A patent/IL107776A0/xx not_active IP Right Cessation
- 1993-11-26 IN IN730CA1993 patent/IN176188B/en unknown
- 1993-11-27 CN CN93120529A patent/CN1047305C/zh not_active Expired - Fee Related
1998
- 1998-09-10 IL IL12617898A patent/IL126178A0/xx unknown

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1069693C (zh) *	1995-09-28	2001-08-15	Basf公司	烷氧基化脂肪纯化的方法
CN1101677C (zh) *	1997-05-30	2003-02-19	韩万愚	含有紫杉醇的药用注射溶液
CN1899615B (zh) *	2001-03-26	2011-02-02	拜尔舍林药物股份公司	预防再狭窄的制剂
WO2009043226A1 (en) *	2007-09-30	2009-04-09	Jiangsu Hengrui Medicine Co., Ltd.	A stable liquid composition comprising taxan derivatives and its preparation method.
CN101829051A (zh) *	2010-05-31	2010-09-15	南昌弘益科技有限公司	1’-乙酰氧基胡椒酚乙酸酯注射液
CN108136071A (zh) *	2015-09-15	2018-06-08	W.L.戈尔及同仁股份有限公司	药物组合物和涂料
US11529441B2 (en)	2015-09-15	2022-12-20	W. L. Gore & Associates, Inc.	Drug composition and coating

Also Published As

Publication number	Publication date
IN176188B (2)	1996-02-24
AU667142B2 (en)	1996-03-07
CN1047305C (zh)	1999-12-15
AU5553894A (en)	1994-06-22
WO1994012198A1 (en)	1994-06-09
CN1095266A (zh)	1994-11-23
IL126178A0 (en)	1999-05-09
ZA938844B (en)	1994-08-02
AU5196793A (en)	1994-06-09
NZ258044A (en)	1995-12-21
IL107776A0 (en)	1994-02-27
KR100371062B1 (ko)	2003-04-21

Legal Events

Date	Code	Title
1994-12-28	C06	Publication
1994-12-28	PB01	Publication
1996-02-14	C10	Entry into substantive examination
1996-02-14	SE01	Entry into force of request for substantive examination
2001-01-10	AD01	Patent right deemed abandoned
2001-01-10	C20	Patent right or utility model deemed to be abandoned or is abandoned

Publication	Publication Date	Title
CN1047305C (zh)	1999-12-15	可注射的组合物
EP0835657B1 (en)	2004-08-25	Stable injectable paclitaxel composition
CN1140297C (zh)	2004-03-03	稳定的药物组合物和稳定化溶剂
CN1192765C (zh)	2005-03-16	紫杉醇制剂
CN1169525C (zh)	2004-10-06	紫杉烷的药物制剂
CN1209059A (zh)	1999-02-24	紫杉烷类组合物及方法
CN1329488A (zh)	2002-01-02	包含类紫杉醇抗肿瘤剂的稳定注射药物组合物
CN1146722A (zh)	1997-04-02	新的以紫杉化合物为主要组分的药物组合物
KR101542364B1 (ko)	2015-08-07	탁산을 포함하는 경구 투여용 약학 조성물
CN1568999A (zh)	2005-01-26	稳定的医药用河豚毒素冷冻干燥制剂
CN1923189A (zh)	2007-03-07	一种紫杉碱类抗癌药物的缓释注射剂
CN1634058A (zh)	2005-07-06	长春瑞滨乳剂及其制备方法
EP3326628A1 (en)	2018-05-30	Pharmaceutical composition for oral administration comprising high concentration taxane
CN1053185A (zh)	1991-07-24	可注射溶液及其制备方法
CN1216608C (zh)	2005-08-31	利福昔明软胶囊组合物
CN1215880C (zh)	2005-08-24	一种外用透皮贴剂的水溶性基质及其制备方法
EP1986630A2 (en)	2008-11-05	A taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
CN1957913A (zh)	2007-05-09	同载铂类化合物和间质水解剂的抗癌药物组合物
CN1272012C (zh)	2006-08-30	一种治疗皮肤病的药物组合物及其制备方法
US20060263327A1 (en)	2006-11-23	Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
CN1973824A (zh)	2007-06-06	同载铂类化合物和雷帕霉素的抗癌组合物
CN1887257A (zh)	2007-01-03	同载铂类化合物和克罗拉滨的抗癌药物组合物
CN1887269A (zh)	2007-01-03	一种含苯达莫司汀及其增效剂的抗癌缓释注射剂
CN1846684A (zh)	2006-10-18	含氨甲喋呤增效剂的缓释注射剂
CN1891703A (zh)	2007-01-10	一种白屈菜红碱复合物及其制备方法